Navigation Links
Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
Date:8/11/2009

looking forward to presenting our data to the Committee in support of Onrigin for its use as a new therapeutic agent for elderly poor-risk AML patients."

The Company reported ending the quarter with $26.1 million in cash and cash equivalents. Based on its current operating plan, management estimates that its existing cash and cash equivalents will be sufficient to fund operations through the second quarter of 2010. The Company's current operating plan assumes that Onrigin will be approved by the FDA in the fourth quarter of 2009 and has limited funds available for commercialization. If Onrigin is approved, the Company will either have to partner with another pharmaceutical company or raise additional capital for the commercialization of Onrigin.

Conference Call

The Company will hold a conference call at 8:30 a.m. Eastern Time on August 13, 2009 to discuss its operations and financial results.

To participate in the conference call, please dial (800) 901-5241 in the U.S. ((617) 786-2963 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 60356125.

An audio webcast of the call will be accessible at www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at

(888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 78450067. The replay will be available through August 27, 20009.


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... 20, 2014 With a mere 19 ... Crist made a brief fundraising stop at the ... , Fresh from a debate last night with his ... stage for the first seven minutes because Crist had ... described the incident in one word: "weird." , Before ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 hc1.com ... a secure cloud solution that enables healthcare organizations ... the ultimate healthcare-specific customer relationship management (“CRM”) solution. ... the unique needs of the healthcare industry, the ... for providers and patients by combining healthcare CRM, ...
Breaking Medicine News(10 mins):Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... who are pre-, perimenopausal with dense breasts benefit most, ... For some women, digital mammography is a better bet ... Women under the age 50 with dense breasts who ... digital mammograms, said study author Dr. Etta Pisano, the ...
... its most selective filter to keep it from clogging with ... St. Louis reveal in a new study. , Researchers ... more vulnerable to dysfunction and disease. , "We speculate ... the filter that can damage it," says senior author Andrey ...
... Xoft, Inc., developer of the,Axxent(R) Electronic ... in,radiation oncology and non-invasive neurosurgery solutions, announced ... agreement., Under the agreement, Elekta will ... Electronic Brachytherapy in the radiation oncology,market. This ...
... Denver Museum of Nature & Science Reveals Plans for New $8 Million ... Interactive Health Science Exhibition ... Jan. 29 Beginning in April 2009, residents and,visitors to the Denver ... their health in ways they have never experienced at a museum,-- or ...
... ... Compliance, and Lowers Costs, NEWARK and EAST BRUNSWICK, N.J., ... empirical,data demonstrating the effectiveness of the Patient Centered Medical Home,(PC-MH), ... their personal physicians and -- when appropriate -- the,patient,s family. ...
... the American Roentgen Ray Society to add more journals ... , BioMed Central, the open access publisher of peer-reviewed ... 4,200 images to the GoldMiner collection. The collection now ... GoldMiner speeds your search for radiology images by quickly ...
Cached Medicine News:Health News:Digital Mammography Better Than Film for Some Women 2Health News:Digital Mammography Better Than Film for Some Women 3Health News:Breakdown of kidney's ability to clean its own filters likely causes disease 2Health News:Breakdown of kidney's ability to clean its own filters likely causes disease 3Health News:Xoft Signs Sales Development Agreement With Elekta 2Health News:Xoft Signs Sales Development Agreement With Elekta 3Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 2Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 3Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 4Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 5Health News:Colorado Residents and Visitors to Investigate Health in a Whole New Way 6Health News:Ground Breaking Program Improves Diabetes Patient Outcomes 2Health News:Ground Breaking Program Improves Diabetes Patient Outcomes 3
(Date:10/22/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a ... reported financial results for the second fiscal quarter ended ... , Revenues of $53.9 million, up 18% over last ... up 33% over last year,s comparable quarter. ... Reference Laboratories (AVRL) of $3.5 million, up 50% over ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... YORK, March 27 The Michael J. Fox ... million total to seven research teams working to ... awarded under the Foundation,s Improving Delivery of ... program is designed to address two major challenges ...
... March 26 Sleep disordered breathing, also ... National Football League (NFL) players, and particularly in linemen, ... players, adds to the growing body of research examining ... investigators say. The study will be presented Tuesday, March ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinson's Disease 2Mayo Clinic: Retired National Football League Linemen Have High Incidence of Sleep Apnea 2Mayo Clinic: Retired National Football League Linemen Have High Incidence of Sleep Apnea 3
Vertigraft femoral shaft an large femoral cross-section designed primarily for use in lumbar corpectomy procedures. Freeze dried preservation....
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... fiber reinforced polymer material emulates the biomechanical ...
... bone graft substitute (beta-tricalcium ... Chronos is an advantageous ... It shortens operative time, ... quantity and quality of ...
... bone regeneration scaffold. Its ... composite ensures ideal osteoconductivity, ... structure maximizes permeability even ... the most meaningful measure ...
Medicine Products: